Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
about
Progress in treatment of ANCA-associated vasculitisCanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides - Executive summaryANCA-associated vasculitis in childhood: recent advances.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis.Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitisSuccessful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic NeuropathyProlonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA).Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisTreatment of ANCA-associated vasculitis, where to go?Indications for use and safety of rituximab in childhood renal diseases.Case of acute, resistant fulminant Wegener's granulomatosis successfully treated by rituximab.Experience with low-dose rituximab in off-label indications at two tertiary hospitals.Impact of rituximab trials on the treatment of ANCA-associated vasculitis.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.B-cell-targeted therapy in adult glomerulonephritis.Treatment of ANCA-associated vasculitis.Vasculitis: an update.Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: A case report and literature review.Twenty-five years of European Union collaboration in ANCA-associated vasculitis research.Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review.Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective.Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management.Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis?[Established medications : new areas of application].Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis.Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.Granulomatosis with Polyangiitis in Children
P2860
Q21195258-8C855B64-B890-4E2B-8850-80DBA40261D8Q26777918-EF07048B-CB1B-4252-A39B-3D96388D6733Q33644574-2A4DD012-C8CB-44FC-A1DB-6AFA026DA6EEQ33683956-7F945E1C-9DAA-4C31-9170-E6CE3A1571BAQ34056484-EC1EEA71-5096-466B-BF9B-43423CF83885Q34282077-EAF6A253-1FFE-439A-91A7-DDA153772638Q34377832-FE766D0E-62BC-4E4E-906B-56F63A98F93EQ35614757-95194233-4F5D-44E7-9B00-60E614ADB6A2Q35725735-C9B91C04-E4FC-4C75-AB37-28A45B1BC7C5Q36152477-87785688-3375-41EA-BB30-0AC9851B6561Q37031689-2D65D000-0511-44A7-900C-125B9555D668Q37640836-E2E0B9E8-21AD-44CA-926A-1B8DC81CE85DQ38016380-A53A9016-CA4C-4CDD-875C-E2D2FECE3EF5Q38044851-4D5AE843-B26C-493E-A81F-E885538A3AD2Q38088389-EC7EB711-96CB-4B72-A779-BC786ABDA2D2Q38126924-C3D0C7F6-6489-4CAB-9851-5A31C2E3CB10Q38152651-D00E9C0B-D1E3-4DB0-B3B2-BB16BA6867FFQ38154934-E69CFEFA-48B4-4C65-A871-625478D0E478Q38159787-BFB72B81-D78E-4E49-A8F3-945EE3597174Q38159916-1D1AA8F7-2049-4A1E-AE11-337D2CFB0E93Q38238796-3805D999-D661-4ABB-83DB-999F105F3E8BQ38367357-F6076B98-8F88-4708-BB49-53C9F4EBC0B1Q38389839-2A6CA91E-5FF6-43D2-86CA-F7D73F748371Q38576072-8A75BA6E-ED48-4566-A435-CF9D3CF5449BQ38965278-3328C976-41D4-4557-AB6F-26362EC1FEA2Q39072021-C567F78C-7EDE-4BCE-BD64-BA1AF8AEB73DQ42239031-98C59DB6-6A7D-4C14-B82F-998B33425182Q42380186-BD5723A2-0867-4FF4-AEDD-7F44AF0D64C7Q44480906-E02D6BEF-0998-45CA-834F-081EA376A038Q45138053-4150EC24-13F0-48D6-AAE7-A1176823D1DAQ50910869-377C285A-A674-48E8-9BB3-5B4DE49F3BABQ50991407-7819A04D-D6D4-4546-8D80-A7577D6F2AE5Q55286318-D9550EDA-B6E0-4E4F-9EFB-B1E5449D0AAAQ59160666-97741596-D1AE-4EEE-B478-0598CD4ECE71
P2860
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recommendations for the use of ...... ntibody-associated vasculitis.
@en
Recommendations for the use of ...... ntibody-associated vasculitis.
@nl
type
label
Recommendations for the use of ...... ntibody-associated vasculitis.
@en
Recommendations for the use of ...... ntibody-associated vasculitis.
@nl
prefLabel
Recommendations for the use of ...... ntibody-associated vasculitis.
@en
Recommendations for the use of ...... ntibody-associated vasculitis.
@nl
P2093
P2860
P356
P1433
P1476
Recommendations for the use of ...... antibody-associated vasculitis
@en
P2093
Alan D Salama
Caroline O S Savage
Charles D Pusey
David G I Scott
David P D'Cruz
David R W Jayne
Lorraine Harper
Mary-Jane C J Guerry
Paul Brogan
Richard A Watts
P2860
P304
P356
10.1093/RHEUMATOLOGY/KER150
P577
2011-05-25T00:00:00Z